IOmx Therapeutics Funding: $125M Raised, Series B (2024)

IOmx Therapeutics funding overview

IOmx Therapeutics is based in Munich, Germany. IOmx Therapeutics has raised $125M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in August 2024. The round record for IOmx Therapeutics runs through 2024; nothing later has been disclosed. Investors on record include Athos, Sofinnova Partners, Wellington Partners, MIG Capital, M Ventures, Arvantis Social Foundation Impact Investment. 6 distinct backers are named across the disclosed rounds.

IOmx Therapeutics at a glance

Total raised: $125M
Latest round: Series B
Latest round date: August 2024
Headquarters: Munich, Germany
Notable investors: Athos, Sofinnova Partners, Wellington Partners, MIG Capital, M Ventures, Arvantis Social Foundation Impact Investment

Frequently asked about IOmx Therapeutics funding

How much has IOmx Therapeutics raised?: IOmx Therapeutics has raised $125M in total disclosed funding across the rounds on record.
Who has invested in IOmx Therapeutics?: Athos, Sofinnova Partners, Wellington Partners, MIG Capital, M Ventures, Arvantis Social Foundation Impact Investment are named among the investors backing IOmx Therapeutics.
What was the latest IOmx Therapeutics funding round?: The most recent disclosed round is a Series B, announced in August 2024.
Where is IOmx Therapeutics based?: IOmx Therapeutics is based in Munich, Germany.
When did IOmx Therapeutics last raise?: The last disclosed IOmx Therapeutics round closed in August 2024 at Series B.

Every IOmx Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Munich at a similar stage.

IOmx Therapeutics Funding: $125M Raised, Series B (2024)

IOmx Therapeutics funding overview

IOmx Therapeutics at a glance

Frequently asked about IOmx Therapeutics funding

Companies related to IOmx Therapeutics (21)

Browse related funding lists (7)